

## Dosing

### Choose once-daily dosing or 3 times weekly dosing

- In both dosing regimens (QD and TIW), 91% of patients achieved two consecutive ≥30% iPTH reductions from baseline
- Dosing must be individualized and based on serum or plasma iPTH levels, with monitoring of serum calcium and serum phosphorus
- The adjacent tables are suggested approaches in titration
- Please see full prescribing information for additional dosing information

Zemplar Capsule	s once-daily dosing
Initia	dose
Baseline iPTH Level ≤500 pg/mL	Baseline iPTH Level >500 pg/ml
1 mcg	2 mcg
Dose adj	ustments
iPTH level relative to baseline	Dose adjustment at 2- to 4-week intervals
The same or increased	Increase by 1 mcg
Decreased by <30%	
Decreased by ≥30%, ≤60%	Maintain dose
Decreased by >60%	Decrease by 1 mcg
iPTH <60 pg/mL	

Initial dose	
Baseline iPTH Level ≤500 pg/mL	Baseline iPTH Level >500 pg/mL
2 mcg	4 mcg
Dose adj	ustments*
iPTH level relative to baseline	Dose adjustment at 2- to 4-week intervals
The same or increased	Increase by 2 mcg
Decreased by <30%	
Decreased by ≥30%, ≤60%	Maintain dose
Decreased by >60%	Decrease by 2 mcg
iPTH <60 pg/mL	

\*To be administered not more often than every other day.

# Zemplar Capsules are available in 3 strengths for multiple dosing options



- No dosing adjustment is required in patients with mild or moderate hepatic impairment
- No overall differences in safety and effectiveness were observed between patients older and younger than 65

years

### **Monitoring instructions**

- During the initial dosing or following any dose adjustment of medication, serum calcium, serum phosphorus, and serum or plasma PTH should be monitored at least every 2 weeks for 3 months, then monthly for 3 months, and every 3 months thereafter
- In clinical trials, if serum calcium was between 10.4 to 11.0 mg/dL, the dose was reduced irrespective of iPTH, and the dose was withheld if serum calcium was >11.0 mg/dL
- PTH and serum calcium levels should be monitored closely and dose adjustments of Zemplar may be required if a patient initiates or discontinues therapy with any strong CYP3A4 inhibitor, such as ketoconazole.

#### No special diet instructions required

• Zemplar Capsules can be taken with or without food

Multiple dosing options allow for individualized treatment of SHPT

Copyright 2006 Abbott Laboratories. Abbott Park, Illinois, U.S.A. Legal Notices/Privacy Policy Terms and Conditions Contact Us

This website and the information contained herein are intended for use by U.S. residents only, are provided for informational purposes only and are not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and must consider the unique characteristics of each patient.